Last-Chance drug access for advanced melanoma patients
NCT ID NCT06063746
Summary
This was a compassionate use program, which allowed continued access to an investigational drug called vidutolimod for patients with melanoma that had stopped responding to other treatments. It was only available to a very specific group of people who had already been receiving the drug in a previous clinical trial. The program is now closed and no longer accepting new participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.